All Pharma News
Paradigm says PhII trial in osteoarthritis shows signs of disease modification

Paradigm says PhII trial in osteoarthritis shows signs of disease modification
GLOBENEWSWIRE
11 Apr 2023
Share Share
Paradigm debuts with $203M series A funding

Paradigm debuts with $203M series A funding
Joseph Keenan FIERCE BIOTECH
31 Jan 2023
Share Share
Paradigm Achieves Primary Endpoint in PARA_OA_008 PII Trial

Paradigm Achieves Primary Endpoint in PARA_OA_008 PII Trial
PRNEWSWIRE
04 Oct 2022
Share Share
Paradigm Partners with NFL Alumni Health on Osteoarthritis Program

Paradigm Partners with NFL Alumni Health on Osteoarthritis Program
PRNEWSWIRE
14 Jul 2022
Share Share
Paradigm Bio begins UK-based screening for PIII study assessing Zilosul

Paradigm Bio begins UK-based screening for PIII study assessing Zilosul
Phoebe Shields PROACTIVEINVESTORS
06 Jul 2022
Share Share
Paradigm Biopharmaceuticals Appoints Marco Polizzi As Chief Executive Officer

Paradigm Biopharmaceuticals Appoints Marco Polizzi As Chief Executive Officer
PRNEWSWIRE
27 Jun 2022
Share Share
Paradigm Biopharma Retains Rubenstein Public Relations as Agency of Record

Paradigm Biopharma Retains Rubenstein Public Relations as Agency of Record
PRNEWSWIRE
19 Apr 2022
Share Share
FDA Grants FTD for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program

FDA Grants FTD for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program
PRNEWSWIRE
13 Apr 2022
Share Share
Paradigm BioPharma Initiates a P 3 Trial in Knee Osteoarthritis Across the U.S

Paradigm BioPharma Initiates a P 3 Trial in Knee Osteoarthritis Across the U.S
PRNEWSWIRE
17 Mar 2022
Share Share
Paradigm Biopharmaceuticals releases positive top-line preclinical study results

Paradigm Biopharmaceuticals releases positive top-line preclinical study results
PROACTIVEINVESTORS
13 Oct 2021
Share Share